Marizyme (Marizyme) Growth Rank : 0 (As of Jun. 02, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Marizyme Growth Rank?

Marizyme has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Marizyme Growth Rank Related Terms

Thank you for viewing the detailed overview of Marizyme's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Marizyme (Marizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marizyme Inc (OTCPK:MRZM) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458

Website

https://www.marizyme.com

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

Executives

Braeden Lichti	10 percent owner	650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7
Nilesh Umedbhai Patel	director	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Michael R Stewart	director	5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044
Harrison Ross	officer: Vice President of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Georgiy Kovalyov	officer: Chief Financial Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
David Barthel	director, officer: Chief Executive Officer	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Bradley Richmond	officer: Acting VP of Finance	555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458
Julie B. Kampf	director	14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410
Vithalbhai D Dhaduk	director	FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512
Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Very Donald Leroy Jr	officer: Executive Vice President	4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739
William Hearl	director	448 SALK CIRCLE, GAITHERSBERG MD 20878
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Catherine J. Pachuk	officer: Chief Science Officer	1033 N. JEAGA DR, JUPITER FL 33458
Satishchandran Chandrasekhar	officer: Chief Operating Officer	167 CARMELA COURT, JUPITER FL 33478